External open innovation partner programIntegrated Analysis Technologies and approaches for Gut Microbiota and Metabolites of Obese Patients.
Obesity involves multiple target molecules/pathways and mechanisms, making it very difficult to research/develop medicines for it. However, efficient drug development can be expected if biomarkers enabling the following are established. Therefore, a comprehensive understanding of gut microbiota and metabolites which change in the pathogenesis of obesity would expedite the search for new biomarkers and targets for drug development.
We are looking forward to collaborating with laboratories which possess cutting-edge mature technologies regarding characterization of micro-biome/intestinal flora from obesity patients.
All proposals will be assessed by our Research & Development team. Based on the level of interest within our research portfolio and the strategic suitability of the proposals with Daiichi Sankyo long-term research focus, we will proceed to discussion with selected candidate(s), potentially leading to funding and partnership agreements.
Proponents who apply for the offer will be contacted within 8 to 10 weeks of submission to clarify additional details concerning the underlying science as well as intellectual property rights, timelines, etc.
We are looking for proposals providing:
- Cutting edge technologies (including Mathematical and advanced statistical models or analytical methodologies) which enable comprehensive interpretation of interstitial flora network and comprehensive interpretation of complicated information from whole genome sequences/comprehensive metabolite analysis.
- Technologies to identify specific gut microbial networks which are relevant to exacerbation of obesity, from obtained omics data
- Access to clinical samples from obesity patients with standardized methods which enable to solve bias and misunderstanding on sample analysis.
- Access to clinical samples from obesity patients at pre- and post-operative bariatric surgery.
In the future, we will use the expertise to select patients who are highly sensitive to anti-obesity drugs and to discover novel drug targets.
Submit a proposal in a form which is available online (it takes about 15 minutes) The proposal should be brief sufficient to provide the main body of the proposal and its innovativeness. The applicant should also provide information about his or her critical knowledge that is applicable for the project, and how the knowledge could be supplemented (i.e., what is additionally required to complete the project). The applicants are strongly encouraged to give us additional information including references or other materials to facilitate the evaluation process.
While Daiichi Sankyo will not share the information beyond its own staff, your initial proposal should contain only non-confidential information.
If your proposal is selected, you will be requested to complete a Confidentiality Disclosure Agreement (CDA).
Biowebspin pays a lot of attention to the privacy, intellectual property, confidentiality and security of its member data.
Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 50 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.
We create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.
Biowebspin is the leading life sciences network with more than 2 million researchers in Biotech, Pharma and Medtech. Biowebspin has a database of 50,000 companies working on 5000 different R&D projects in more than 50 topics, organized in 10 main types of partnering programs with Academia.